BioMarin Pharma (BMRN) Tops Q4 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 --0%
EPS Growth %: -34.0%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: -34.0%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.00, which may not compare to the analyst estimate of ($0.06). Revenue for the quarter came in at $537.5 million versus the consensus estimate of $537.62 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.61. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 billion, versus the consensus of $2.58 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
- Robinhood prices $2B convertible notes offering due 2029
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
